Diagnostic and predictive value of urine PCA3 gene expression for the clinical management of patients with altered prostatic specific antigen;Valor diagnóstico y predictivo del estudio en orina del gen PCA3 para el manejo clínico de pacientes con antígeno prostático específico alterado

Actas Urologicas Espanolas

Volumn 38, Issue 3, 2014, Pages 150-155

  Rodon N ^a   Trias I ^a,b   Verdu M ^a,b   Roman R ^a   Dominguez A ^c   Calvo, M ^d   Banus, J M ^c   Ballesta, A M ^e   Maestro, M L ^f   Puig, X ^a,b,g  

^a BIOPAT   (Spain)

^b Histopat Laboratoris   (Spain)

^c ICUN   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

^e Hospital Moncloa   (Spain)

^f HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^g Scias Hospital Barcelona   (Spain)

Author keywords

Gleason; PCA3; Prostate cancer; Prostatic specific antigen; Screening; Tumor aggressiveness

Indexed keywords

PROSTATE CANCER ANTIGEN 3, HUMAN; PROSTATE SPECIFIC ANTIGEN; TUMOR ANTIGEN; TUMOR MARKER; TUMOR PROTEIN;

ADENOCARCINOMA; AGED; BIOSYNTHESIS; BLOOD; CANCER GRADING; CLINICAL TRIAL; EARLY DIAGNOSIS; GENETICS; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; NEEDLE BIOPSY; PATHOLOGY; PREDICTIVE VALUE; PROSPECTIVE STUDY; PROSTATE TUMOR; TUMOR INVASION; UNNECESSARY PROCEDURE; URINE;

ADENOCARCINOMA; AGED; ANTIGENS, NEOPLASM; BIOPSY, NEEDLE; EARLY DETECTION OF CANCER; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; UNNECESSARY PROCEDURES;

EID: 84897384077     PISSN: 02104806     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.acuro.2013.07.009     Document Type: Article

References (25)

1. F.H. Schröder, J. Hugosson, M.J. Roobol, T.L. Tammela, S. Ciatto, V. Nelen ERSPC Investigators Screening and prostate-cancer mortality in a randomized European study N Engl J Med 360 2009 1320 1328
2. A. Pérez-Lanzac-Lorca, A. Barco-Sánchez, E. Romero, A. Martínez-Peinado, F. López-Elorza, and E. Sánchez- Sánchez et al. Correlación del cociente PSA complex/PSA total con el cociente PSA libre/PSA total, sensibilidad y especificidad de ambos marcadores para el diagnóstico del cáncer de próstata Actas Urol Esp. 37 2013 498 503
3. C. Baumann, and T.E. Behbahani EAU guidelines for prostate cancer: To screen or not to screen? Actas Urol Esp 36 2012 1
4. T.J. Wilt, M.K. Brawer, K.M. Jones, M.J. Barry, W.J. Aronson, S. Fox Prostate Cancer Intervention versus Observation Trial (PIVOT) Study Group Radical prostatectomy versus observation for localized prostate cancer N Engl J Med 367 2012 203 213
5. C.M. Coley, M.J. Barry, C. Fleming, and A.G. Mulley Early detection of prostate cancer. Part I: Prior probability and effectiveness of tests. The American College of Physicians Ann Intern Med 126 1997 394 406
6. G.L. Andriole, E.D. Crawford, R.L. Grubb 3rd, S.S. Buys, D. Chia, T.R. Church PLCO Project Team Mortality results from a randomized prostate-cancer screening trial N Engl J Med 360 2009 1310 1319
7. V.A. Moyer U.S. Preventive Service Task Force Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement Ann Intern Med 157 2012 120 134
8. A. Fernández-Serra, J. Rubio-Briones, Z. García-Casado, J.A. Solsona, and J.A. López-Guerrero Prostate cancer: The revolution of the fusion genes Actas Urol Esp 35 2011 420 428
9. M.N. Ribeiro da Silva, M. Tobias-Machado, A.C. Lima-Pompeo, L.O. Reis, and M.A. da Silva Pinhal Prostate cancer: Promising biomarkers related to aggressive disease Actas Urol Esp 36 2012 484 490
10. M.J. Bussemakers, A. van Bokhoven, G.W. Verhaegh, F.P. Smit, H.F. Karthaus, and J.A. Schalken et al. DD3: A new prostate-specific gene, highly overexpressed in prostate cancer Cancer Res 59 1999 5975 5979
11. D. Hessels, and J.A. Schalken The use of PCA3 in the diagnosis of prostate cancer Nat Rev Urol 6 2009 255 261
12. J. Groskopf, S.M. Aubin, I.L. Deras, A. Blase, S. Bodruq, and C. Clark et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer Clin Chem 52 2006 1089 1095
13. J. Ruiz-Aragón, and S. Márquez-Peláez Evaluación del test PCA3 para el diagnóstico de cáncer de próstata: revisión sistemática y metanálisis Actas Urol Esp 34 2010 346 355
14. J. Rubio-Briones, A. Fernández-Serra, M. Ramírez, L. Rubio, A. Collado, and J. Casanova et al. Outcomes of expanded use of PCA3 testing in a Spanish population with clinical suspicion of prostate cancer Actas Urol Esp 35 2011 589 596
15. J.R. Day, M. Jost, M.A. Reynolds, J. Groskopf, and H. Rittenhouse PCA3: from basic molecular science to the clinical lab Cancer Lett 301 2011 1 6
16. H. Van Poppel, A. Haese, M. Graefen, A. de la Taille, J. Irani, and T. de Reijke et al. The relationship between Prostate CAncer gene 3 (PCA3) and prostate cancer significance BJU Int 109 2012 360 366
17. A. Heidenreich, J. Bellmunt, M. Bolla, S. Joniau, M. Manson, and V. Matveev et al. Guía de la EAU sobre el cáncer de próstata. Parte I: cribado, diagnóstico y tratamiento del cáncer clínicamente localizado Actas Urol Esp 35 2011 501 514
18. J.I. Epstein, W.C. Allsbrook Jr., M.B. Amin, L.L. Egevad ISUP Grading Committe The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma Am J Surg Pathol 29 2005 1228 1242
19. Friendly M. Working with categorical data with R and the vcd and vcdExtra packages. York University, Toronto [publicado 26 Jun 2013]. Disponible en: http://cran.r-project.org/web/packages/vcdExtra/vignettes/vcd-tutorial.pdf
20. R Development Core Team R: A language and environment for statistical computing 2011 R Foundation for Statistical Computing Vienna, Austria ISBN 3-900051-07-0
21. S. De Luca, R. Passera, A. Milillo, R. Coda, and D.F. Randone Histological chronic prostatitis and high-grade prostate intra-epithelial neoplasia do not influence urinary prostate cancer gene 3 score BJU Int 110 2012 E778 E782
22. A. Haese, A. de la Taille, H. van Poppel, M. Marberger, A. Stenzl, and P.F. Mulders et al. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy Eur Urol 54 2008 1081 1088
23. A. De la Taille, J. Irani, M. Graefen, F. Chun, T. de Reijke, and P. Kil et al. Clinical evaluation of the PCA3 assay in guiding initial biopsy decisions J Urol 185 2011 2119 2125
24. S.F. Shariat, D.S. Scherr, A. Gupta, F.J. Bianco Jr., P.I. Karakiewicz, and I.S. Zeltser et al. Emerging biomarkers for prostate cancer diagnosis, staging, and prognosis Arch Esp Urol 64 2011 681 694
25. M. Remzi, Y.K. Fong, M. Dobrovits, T. Anagnostou, C. Seitz, and M. Waldert et al. The Vienna nomogram: Validation of a novel biopsy strategy defining the optimal number of cores based on patient age and total prostate volume J Urol 174 2005 1256 1260 discussion 1260-1251; author reply 1261